X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs DISHMAN PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH DISHMAN PHARMA PANACEA BIOTECH/
DISHMAN PHARMA
 
P/E (TTM) x 80.9 25.1 322.2% View Chart
P/BV x 1.8 3.3 53.7% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PANACEA BIOTECH   DISHMAN PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
DISHMAN PHARMA
Mar-16
PANACEA BIOTECH/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs149374 39.7%   
Low Rs82129 63.8%   
Sales per share (Unadj.) Rs84.1197.8 42.5%  
Earnings per share (Unadj.) Rs-18.321.2 -86.3%  
Cash flow per share (Unadj.) Rs-6.734.7 -19.3%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs83.7179.9 46.5%  
Shares outstanding (eoy) m61.2580.69 75.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.41.3 107.9%   
Avg P/E ratio x-6.311.9 -53.2%  
P/CF ratio (eoy) x-17.27.2 -237.9%  
Price / Book Value ratio x1.41.4 98.6%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m7,07420,306 34.8%   
No. of employees `0002.80.8 331.7%   
Total wages/salary Rs m1,4495,355 27.1%   
Avg. sales/employee Rs Th1,874.119,252.7 9.7%   
Avg. wages/employee Rs Th527.06,459.5 8.2%   
Avg. net profit/employee Rs Th-407.72,064.1 -19.8%   
INCOME DATA
Net Sales Rs m5,15415,961 32.3%  
Other income Rs m100265 37.6%   
Total revenues Rs m5,25416,226 32.4%   
Gross profit Rs m-7664,103 -18.7%  
Depreciation Rs m7111,091 65.2%   
Interest Rs m1,503944 159.1%   
Profit before tax Rs m-2,8812,334 -123.4%   
Minority Interest Rs m110-   
Prior Period Items Rs m-61 -518.2%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17624 2.7%   
Profit after tax Rs m-1,1211,711 -65.5%  
Gross profit margin %-14.925.7 -57.8%  
Effective tax rate %-0.626.7 -2.2%   
Net profit margin %-21.810.7 -202.9%  
BALANCE SHEET DATA
Current assets Rs m3,81011,018 34.6%   
Current liabilities Rs m8,3659,517 87.9%   
Net working cap to sales %-88.49.4 -939.9%  
Current ratio x0.51.2 39.3%  
Inventory Days Days156110 140.9%  
Debtors Days Days6735 193.0%  
Net fixed assets Rs m14,48016,304 88.8%   
Share capital Rs m61161 38.0%   
"Free" reserves Rs m90312,907 7.0%   
Net worth Rs m5,12714,516 35.3%   
Long term debt Rs m5,8324,189 139.2%   
Total assets Rs m19,43329,805 65.2%  
Interest coverage x-0.93.5 -26.4%   
Debt to equity ratio x1.10.3 394.1%  
Sales to assets ratio x0.30.5 49.5%   
Return on assets %2.08.9 22.0%  
Return on equity %-21.911.8 -185.5%  
Return on capital %3.617.5 20.7%  
Exports to sales %24.524.8 98.9%   
Imports to sales %10.23.7 272.6%   
Exports (fob) Rs m1,2643,956 31.9%   
Imports (cif) Rs m525596 88.0%   
Fx inflow Rs m1,5394,952 31.1%   
Fx outflow Rs m942697 135.2%   
Net fx Rs m5974,255 14.0%   
CASH FLOW
From Operations Rs m5992,786 21.5%  
From Investments Rs m-438-1,529 28.6%  
From Financial Activity Rs m-303-941 32.2%  
Net Cashflow Rs m-141316 -44.7%  

Share Holding

Indian Promoters % 74.5 61.4 121.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 3.7 16.2%  
FIIs % 1.3 12.7 10.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 22.1 106.8%  
Shareholders   10,259 46,261 22.2%  
Pledged promoter(s) holding % 35.1 35.8 98.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   UNICHEM LAB  VENUS REMEDIES  STERLING BIOTECH  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 17, 2017 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS